



Clinical trial results: Continued access to darunavir/ritonavir (DRV/r) in HIV-1 infected children and adolescents aged 3 years and above.

Summary

EudraCT number	2009-017013-29
Trial protocol	GB ES FR IT
Global end of trial date	23 November 2017

Results information

Result version number	v1 (current)
This version publication date	08 June 2018
First version publication date	08 June 2018

Trial information

Trial identification

Sponsor protocol code	TMC114-TIDP29-C232
-----------------------	--------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01138605
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	JANSSEN SCIENCES IRELAND UC
Sponsor organisation address	Eastgate Village, Eastgate Little Island, Ireland,
Public contact	Clinical Registry Group, JANSSEN SCIENCES IRELAND UC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, JANSSEN SCIENCES IRELAND UC, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 November 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 November 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the study was to continue the provision of darunavir (DRV) for paediatric subjects who had completed treatment with DRV in the clinical studies TMC114-C212, TMC114- TiDP29-C228, or TMC114-TiDP29-C230 sponsored by Tibotec Pharmaceuticals (now Janssen Research and Development), and who continued to benefit from using it, in countries where DRV was not commercially available for paediatric subjects, was not reimbursed, or could not be accessed through another source (Example, access program, governmental program). In addition, information on the safety of DRV/rtv in combination with other ARVs was assessed.

Protection of trial subjects:

The safety assessments included laboratory assessments (hematology, biochemistry including pancreatic amylase [if available] or lipase and lipid analyses), pregnancy tests (serum chemistry and urinalysis). Adverse events were assessed throughout the study.

Background therapy:

Ritonavir and Optimized Background Regimen (OBR)

Evidence for comparator: -

Actual start date of recruitment	13 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 13
Country: Number of subjects enrolled	Brazil: 8
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	India: 1
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Ukraine: 6
Country: Number of subjects enrolled	South Africa: 14
Worldwide total number of subjects	46
EEA total number of subjects	4

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	21
Adolescents (12-17 years)	25
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects enrolled in this study TMC114-TIDP29-C232 included subjects who were previously enrolled in study TMC114-C212, TMC114-TiDP29-C228, and TMC114-TiDP29-C230. A total of 46 subjects from previous TMC studies were found eligible to be enrolled in this study.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)

Arm description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C212 study continued to receive oral administration of Darunavir (DRV) 375-600 milligram (mg) tablets or oral suspension (depending on body weight) along with Ritonavir (rtv) 100 mg tablet or capsule or liquid (80 mg/mL) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Arm type	Experimental
Investigational medicinal product name	Darunavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension, Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of Darunavir 375-600 milligram (mg) tablet or oral suspension twice daily.

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Capsule, Oral liquid
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of ritonavir 100 mg tablet or capsule or liquid (80 mg/mL) twice daily.

Arm title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)
------------------	--

Arm description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C228 study continued to receive oral administration of Darunavir 200-375 milligram (mg) tablets or oral suspension (100 mg/mL) (depending on body weight) along with ritonavir 60-100 mg tablet or oral solution (80 mg/mL) (depending on body weight) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution, Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of ritonavir 60-100 mg tablet or oral solution (80 mg/mL) (depending on body weight) twice daily.

Investigational medicinal product name	Darunavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of Darunavir 200-375 milligram (mg) tablets or oral suspension (100 mg/mL) (depending on body weight) twice daily.

Arm title	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)
------------------	---

Arm description:

Subjects received oral administration of Darunavir/Ritonavir 800 mg (2*400 mg tablets)/100 mg tablets once daily.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of ritonavir 100 mg tablet once daily.

Investigational medicinal product name	Darunavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received oral administration of Darunavir 800 milligram (mg) (2*400 mg tablets) tablets once daily.

Number of subjects in period 1	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)
Started	16	20	10
Completed	0	0	0
Not completed	16	20	10
Subject lost to follow-up	1	1	-
Consent withdrawn by subject	-	3	-
Adverse event/hiv related	1	-	1
Other	4	10	3
Subject non-compliant	1	2	2

Switch to commercially available medication	7	3	2
Subject ineligible to continue the trial	1	1	2
Lack of efficacy	1	-	-

Baseline characteristics

Reporting groups

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C212 study continued to receive oral administration of Darunavir (DRV) 375-600 milligram (mg) tablets or oral suspension (depending on body weight) along with Ritonavir (rtv) 100 mg tablet or capsule or liquid (80 mg/mL) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C228 study continued to receive oral administration of Darunavir 200-375 milligram (mg) tablets or oral suspension (100 mg/mL) (depending on body weight) along with ritonavir 60-100 mg tablet or oral solution (80 mg/mL) (depending on body weight) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)
-----------------------	---

Reporting group description:

Subjects received oral administration of Darunavir/Ritonavir 800 mg (2*400 mg tablets)/100 mg tablets once daily.

Reporting group values	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)
Number of subjects	16	20	10
Title for AgeCategorical Units: subjects			
Children (2-11 years)	1	20	0
Adolescents (12-17 years)	15	0	10
Adults (18-64 years)	0	0	0
From 65 to 84 years	0	0	0
85 years and over	0	0	0
Title for AgeContinuous Units: years			
median	15	5	14.5
full range (min-max)	11 to 17	4 to 6	13 to 17
Title for Gender Units: subjects			
Female	6	10	6
Male	10	10	4

Reporting group values	Total		
Number of subjects	46		
Title for AgeCategorical Units: subjects			
Children (2-11 years)	21		
Adolescents (12-17 years)	25		
Adults (18-64 years)	0		
From 65 to 84 years	0		
85 years and over	0		

Title for AgeContinuous Units: years median full range (min-max)	-		
Title for Gender Units: subjects			
Female	22		
Male	24		

End points

End points reporting groups

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C212 study continued to receive oral administration of Darunavir (DRV) 375-600 milligram (mg) tablets or oral suspension (depending on body weight) along with Ritonavir (rtv) 100 mg tablet or capsule or liquid (80 mg/mL) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C228 study continued to receive oral administration of Darunavir 200-375 milligram (mg) tablets or oral suspension (100 mg/mL) (depending on body weight) along with ritonavir 60-100 mg tablet or oral solution (80 mg/mL) (depending on body weight) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)
-----------------------	---

Reporting group description:

Subjects received oral administration of Darunavir/Ritonavir 800 mg (2*400 mg tablets)/100 mg tablets once daily.

Primary: Number of Subjects With Adverse Events (AEs)

End point title	Number of Subjects With Adverse Events (AEs) ^[1]
-----------------	---

End point description:

An adverse event (AE) is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. The intent-to-population (ITT) population included all subjects who have taken at least one dose of DRV.

End point type	Primary
----------------	---------

End point timeframe:

Approximately 7 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	20	10	
Units: Subjects	6	5	4	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Serious Adverse Events (SAEs)

End point title	Number of Subjects With Serious Adverse Events (SAEs) ^[2]
-----------------	--

End point description:

A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The intent-to-population (ITT) population included all subjects who have taken at least one dose of DRV.

End point type	Primary
----------------	---------

End point timeframe:

Approximately 7 years

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily (q.d) (C230)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	20	10	
Units: Subjects	5	4	3	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Approximately 7 years

Adverse event reporting additional description:

The intent-to-population (ITT) population included all subjects who have taken at least one dose of DRV.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

Reporting groups

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C212 study continued to receive oral administration of Darunavir (DRV) 375-600 milligram (mg) tablets or oral suspension (depending on body weight) along with Ritonavir (rtv) 100 mg tablet or capsule or liquid (80 mg/mL) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)
-----------------------	--

Reporting group description:

HIV-1 infected subjects who were participating in the TMC114-TiDP29-C228 study continued to receive oral administration of Darunavir 200-375 milligram (mg) tablets or oral suspension (100 mg/mL) (depending on body weight) along with ritonavir 60-100 mg tablet or oral solution (80 mg/mL) (depending on body weight) twice daily. Subjects who experienced tolerability issues with the rtv liquid or powder (or oral suspension) formulation and/or were at risk of discontinuing DRV/rtv based on investigator assessment were allowed to switch to one 100-mg capsule or tablet rtv bid.

Reporting group title	Darunavir/Ritonavir (DRV/rtv) once daily q.d. (C230)
-----------------------	--

Reporting group description:

Subjects received oral administration of Darunavir/Ritonavir 800 mg (2*400 mg tablets)/100 mg tablets once daily.

Serious adverse events	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily q.d. (C230)
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 16 (31.25%)	4 / 20 (20.00%)	3 / 10 (30.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Femur Fracture			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			

subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb Injury			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road Traffic Accident			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Autonomic Nervous System Imbalance			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Convulsion			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status Migrainosus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Eye disorders			
Cataract			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uveitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal Obstruction			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular Torsion			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide Attempt			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic Inflammatory Disease			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 16 (12.50%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C212)	Darunavir/Ritonavir (DRV/rtv) twice a day (b.i.d) (C228)	Darunavir/Ritonavir (DRV/rtv) once daily q.d. (C230)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 16 (12.50%)	1 / 20 (5.00%)	2 / 10 (20.00%)
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Skin and subcutaneous tissue disorders			
Lipoatrophy			
subjects affected / exposed	0 / 16 (0.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Lipodystrophy Acquired			
subjects affected / exposed	1 / 16 (6.25%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			

Gastroenteritis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1
---	---------------------	---------------------	----------------------

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 August 2010	The overall reason for the amendment was to update the DRV dose for children weighing between 10 and <20 killogram(kg) from 20 to 25 milligram/killogram (mg/kg), to add a table with different doses/weight, and to change the emergency number.
23 May 2012	The overall reason for the amendment was to change the DRV/rtv dose recommendation for subjects weighing 10 to <15 kg from DRV/rtv 25/3 mg/kg bid to 20/3 mg/kg bid, to allow local provision of liquid rtv (80 mg/mL oral solution), and to clarify the need of confirmation of the body weight before a DRV/rtv dose reduction.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Limitation of this study was - only serious adverse events (SAEs), AEs leading to discontinuation or drug-related AEs were captured.

Notes: